Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)5,465.00
  • Today's Change-15.00 / -0.27%
  • Shares traded917.00
  • 1 Year change+33.88%
  • Beta0.2422
Data delayed at least 20 minutes, as of Oct 28 2021 09:06 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

As of last trade Genus PLC (GNS:LSE) traded at 5,465.00, -13.39% below its 52-week high of 6,310.00, set on Sep 07, 2021.
52-week range
Today
3,896.00Dec 10 20206,310.00Sep 07 2021
Markit short selling activity
Low
Med
High
Open5,500.00
High5,500.00
Low5,455.00
Bid5,470.00
Offer5,475.00
Previous close5,480.00
Average volume131.36k
Shares outstanding65.77m
Free float65.35m
P/E (TTM)76.05
Market cap3.60bn GBP
EPS (TTM)0.7206
GBP
Annual div (ADY)32.00
GBX
Annual div yield (ADY)0.58%
Div ex-dateMar 04 2021
Div pay-dateApr 01 2021
Next div ex-dateNov 18 2021
Next div pay-dateDec 10 2021
Data delayed at least 20 minutes, as of Oct 28 2021 09:06 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Genus PLC shares was Hold at 5,284.00 on 09 Sep 2021Read the full article

Board of Directors

1/8

Iain Ferguson, Non-Executive Chairman

2/8

Stephen Wilson, Chief Executive

3/8

Alison Henriksen, Chief Financial Officer

4/8

Lysanne Gray, Non-Executive Director

5/8

Lykele van der Broek, Non-Executive Director

6/8

Lesley Knox, Senior Independent Director

7/8

Professor Jason Chin, Non-Executive Director (no image available)

8/8

Dan Hartley, Group General Counsel and Company Secretary

Contact

Registered Office:
Genus plc
Matrix House
Basing View
Basingstoke
Hampshire
RG21 4DZ

Registered number: 2972325
T: +44(0)1256 347100
F: +44 (0)1256 477385

For all investor related enquiries, please contact:
Buchanan: Charles Ryland / Chris Lane / Sophie Wills

T: +44 (0) 207 466 5000
E: charlesr@buchanan.uk.com / victoriaw@buchanan.uk.com

2021 Preliminary Results

An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.